A pharmaceutical composition can be provide for treating or preventing heart failure. Additionally, siRNA and a vector expressing said siRNA can be provided that can be used in the pharmaceutical composition for treating or preventing heart failure. For example, a pharmaceutical composition can be provided for treating or preventing heart failure that contains a DNA sequence encoding RNA containing a sense strand sequence of consecutive 18 to 29 nucleotides from angiopoietin-like protein 2 (ANGPTL2) mRNA or the alternative splicing type RNA thereof and an antisense strand sequence complementary to the sense strand sequence under control of a promoter, and a pharmaceutically acceptable carrier.

Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Ig light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig light chains, in whole or in part, that are encoded by human Ig light chain-encoding sequences inserted into an endogenous Ig light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.

The present invention provides systems and non-invasive methods for gender selection of eukaryotic organisms More specifically, the invention applies the CRISPR-Cas system as well as any derivatives and fusion proteins thereof for creation of transgenic eukaryotic organisms and for selecting the desired gender of the resulting progeny.

An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.

The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.

The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.

The present invention provides polypeptides and nucleic acid molecules that are useful in identifying.

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.

The present invention relates to a method for the generation of V.sub.H heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a V.sub.H heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous V.sub.H heavy chain locus in that mammal.

An insect gene drive system for biocontrol of a population of an insect is provided. The gene drive system includes: a) a first DNA sequence encoding a toxin under the control of a maternal germline-specific promoter active in the insect, with the first DNA sequence being linked to b) a second DNA sequence encoding an antidote under the control of an early embryo-specific promoter active in the insect. The toxin is expressed in maternal germline cells of the insect and results in maternal-effect lethality in the insect, and the antidote is expressed in embryos of the insect and counters the maternal-effect lethality. In some embodiments, the insect is Drosophila suzrukii.